Q1 Earnings Forecast for ALDX Issued By HC Wainwright

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Aldeyra Therapeutics in a research note issued on Monday, March 3rd. HC Wainwright analyst M. Caufield anticipates that the biotechnology company will post earnings per share of ($0.25) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at $0.08 EPS, FY2028 earnings at $0.48 EPS and FY2029 earnings at $1.00 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.30).

Aldeyra Therapeutics Stock Down 0.3 %

Shares of ALDX stock opened at $6.15 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. Aldeyra Therapeutics has a 1-year low of $2.71 and a 1-year high of $6.92. The firm has a fifty day moving average of $5.53 and a two-hundred day moving average of $5.40.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. State Street Corp lifted its position in shares of Aldeyra Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock worth $5,249,000 after buying an additional 16,188 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock worth $2,571,000 after buying an additional 295,864 shares during the last quarter. Barclays PLC lifted its position in shares of Aldeyra Therapeutics by 280.1% in the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock worth $353,000 after buying an additional 48,313 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Aldeyra Therapeutics by 14.4% in the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock worth $112,000 after buying an additional 2,822 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in shares of Aldeyra Therapeutics in the 4th quarter worth about $234,000. 59.71% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.